What is the Protégé Encore study?
The Protégé Encore study will further evaluate the safety of the study drug and test whether it will stop or slow the progression of the autoimmune disease that damages beta cells.
Our bodies use a type of white blood cells, called T cells, to attack cells and germs that are foreign to the body. In people with type 1 diabetes, the body acts as if the insulin-producing beta cells in the pancreas are foreign and allow certain T cells to attack the beta cells.
To slow the effects of type 1 diabetes, the beta cells need a way to protect themselves from the body's attack. The Protégé Encore study is testing an investigational study drug, a CD3 monoclonal antibody to see if it will protect the beta cells. Teplizumab may protect beta cells by attaching to T cells before the T cells can attack the beta cells.
To learn more, please visit: www.clinicaltrials.gov.